BeOne Medicines (BEIGF) Non-Current Assets (2015 - 2026)

BeOne Medicines (BEIGF) has reported Non-Current Assets for 12 consecutive years, with $2.0 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Assets fell 1.43% year-over-year to $2.0 billion in Q2 2026; TTM through Jun 2026 was $2.0 billion, a 1.43% decrease from a year earlier, with the FY2025 full-year figure at $2.0 billion, up 1.33% from the prior year.
• Non-Current Assets was $2.0 billion for Q2 2026 at BeOne Medicines, roughly flat from $2.0 billion in the prior quarter.
• Over five years, Non-Current Assets peaked at $2.0 billion in Q2 2025 and troughed at $976.8 million in Q3 2022.
• A 5-year average of $1.6 billion and a median of $1.8 billion in 2024 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets jumped 57.82% in 2022 and dropped 1.43% in 2026, its largest moves.
• Over 5 years, Non-Current Assets stood at $1.2 billion in 2022, then surged by 36.65% to $1.6 billion in 2023, then gained by 20.44% to $1.9 billion in 2024, then grew by 1.33% to $2.0 billion in 2025, then gained by 0.25% to $2.0 billion in 2026.
• The last three Non-Current Assets figures came in at $2.0 billion (Q2 2026), $2.0 billion (Q1 2026), and $2.0 billion (Q4 2025), per Business Quant data.